RP1
Phase 2Small molecule
RP1 is one of 113 small molecule programs targeting Melanoma. It is currently in Phase 2.
4
Indications
4
Total Trials
3
Active Trials
112
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Cotellic
RochePhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Libtayo
RegeneronPhase 3
Opdualag
Bristol-Myers SquibbPhase 3
Intron a
Merck & Co.Phase 3
Fabhalta
RegeneronPhase 3
Talimogene Laherparepvec
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Skin Cancer1 trial
Squamous Cell Carcinoma1 trial
Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RP1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RReplimune Inc.